Compare HLF & ARDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HLF | ARDX |
|---|---|---|
| Founded | 1980 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.6B |
| IPO Year | N/A | 2014 |
| Metric | HLF | ARDX |
|---|---|---|
| Price | $17.07 | $7.74 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $16.00 | $12.95 |
| AVG Volume (30 Days) | 1.6M | ★ 6.4M |
| Earning Date | 02-18-2026 | 02-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.95 | N/A |
| EPS | ★ 3.11 | N/A |
| Revenue | ★ $4,961,900,000.00 | $398,234,000.00 |
| Revenue This Year | $1.12 | $22.58 |
| Revenue Next Year | $2.97 | $32.18 |
| P/E Ratio | $5.59 | ★ N/A |
| Revenue Growth | N/A | ★ 58.12 |
| 52 Week Low | $5.04 | $3.21 |
| 52 Week High | $17.67 | $8.40 |
| Indicator | HLF | ARDX |
|---|---|---|
| Relative Strength Index (RSI) | 64.60 | 61.18 |
| Support Level | $16.40 | $7.59 |
| Resistance Level | $17.60 | $8.02 |
| Average True Range (ATR) | 0.68 | 0.43 |
| MACD | -0.05 | -0.02 |
| Stochastic Oscillator | 61.84 | 60.78 |
Herbalife Ltd is an international nutrition company that provides health and wellness products to consumers in 95 markets, which consist of countries and territories, through their direct-selling business model. Companies' products are weight management, targeted nutrition, Energy, Sports and Fitness, Outer Nutrition and Literature, Promotional, and Other. Weight management generates the majority of revenue from products like Meal replacements, protein shakes, drink mixes, weight loss enhancers, and healthy snacks. Geographically, the main segments are North America, Latin America, EMEA, Asia Pacific regions, and China.
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.